

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Shimkets et al.

Examiner:

Serial No.:

Art Unit:

Filed: concurrently herewith

For: NUCLEIC ACIDS CONTAINING SINGLE NUCLEOTIDE POLYMORPHISMS AND  
METHODS OF USE THEREOF

Mail Stop:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**PRELIMINARY AMENDMENT**

Prior to examination of the above-identified patent application, please amend the application as set forth below.

Please cancel Claim 1.

Please add the following claims 47-51:

47. (new) An isolated polypeptide, wherein the polypeptide is encoded by a polynucleotide comprising the polymorphic nucleotide sequence of SEQ ID NO: 400.
48. (new) An isolated polypeptide less than 50 amino acids in length comprising the amino acid sequence EVAPEASTSSASQVIA.
49. (new) An isolated polypeptide consisting of the amino acid sequence EVAPEASTSSASQVIA.
50. (new) An isolated polymorphic polynucleotide comprising a nucleic acid sequence selected from the group consisting of sequences SEQ ID NOS:1-1468, or its complement, wherein said nucleic acid sequence includes a nucleotide selected from the group consisting of the nucleotide recited in Table 1, column 5 and the nucleotide recited in Table 1, column 6, for said nucleic acid sequence, or the complement includes a nucleotide complementary to the nucleotide recited in Table 1, column 5, or the nucleotide recited in Table 1, column 6, for said nucleic acid sequence.

51. (new) An isolated polypeptide comprising a polymorphic site at one or more amino acid residues, wherein the polypeptide is encoded by a nucleic acid sequence selected from the group consisting of sequences SEQ ID NOS:1-1468, or its complement, wherein said nucleic acid sequence includes a nucleotide selected from the group consisting of the nucleotide recited in Table 1, column 5 and the nucleotide recited in Table 1, column 6 for said nucleic acid sequence, or the complement includes a nucleotide complementary to the nucleotide recited in Table 1, column 5, or the nucleotide recited in Table 1, column 6 for said nucleic acid sequence.

A listing of all claims before the Examiner following the filing of this application may be found on page 3, hereof.